IMPROVING THE LIVES OF PEOPLE WITH NEURODEVELOPMENTAL DISABILITIES H1 2026 Results Webinar 26 August 2026 Forward looking statements This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward...
Investor presentation, 26 August 2026
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Growing royalty anchors Neuren first ever dividend program
- Half Yearly Report and Accounts
- European Commission grants marketing authorisation for DAYBU
- Neuren H1 2026 Financial Results Webinar on 26 August 2026
- Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded
Later from Neuren Pharmaceuticals
- Dividend/Distribution - NEU
- Corporate Presentation, 2 September 2026
- Update - Dividend/Distribution - NEU
- Pause in Trading
- Trofinetide US patent protections extended to March 2041
